ABSTRACT
Recent improvements in mRNA display have enabled the selection of peptides that incorporate non-natural amino acids, thus expanding the chemical diversity of macrocycles beyond what is accessible in nature. Such libraries have incorporated non-natural amino acids at the expense of natural amino acids by reassigning their codons. Here we report an alternative approach to expanded amino-acid diversity that preserves all 19 natural amino acids (no methionine) and adds 6 non-natural amino acids, resulting in the highest sequence complexity reported to date. We have applied mRNA display to this 25-letter library to select functional macrocycles that bind human STING, a protein involved in immunoregulation. The resulting STING-binding peptides include a 9-mer macrocycle with a dissociation constant (KD ) of 3.4â nM, which blocks binding of cGAMP to STING and induces STING dimerization. This approach is generalizable to expanding the amino-acid alphabet in a library beyond 25 building blocks.
Subject(s)
Membrane Proteins/metabolism , Peptides, Cyclic/metabolism , RNA, Messenger/metabolism , Amino Acid Sequence , Amino Acids/chemistry , Codon , Cyclic AMP/chemistry , Cyclic AMP/metabolism , Cyclic GMP/chemistry , Cyclic GMP/metabolism , Dimerization , Genetic Engineering , Humans , Kinetics , Membrane Proteins/chemistry , Peptide Library , Peptides, Cyclic/chemistry , RNA, Messenger/geneticsABSTRACT
We report the identification of potent agonists of the Glucagon-Like Peptide-1 receptor (GLP-1R) via evaluation of two positional scanning libraries and a two-dimensional focused library, synthesized in part on SynPhase Lanterns. These compounds are 11 amino acid peptides containing several unnatural amino acids, including (in particular) analogs of biphenylalanine (Bip) at the two C-terminal positions. Typical activities of the most potent peptides in this class are in the picomolar range in an in vitro functional assay using human GLP-1 receptor.
Subject(s)
Peptides/chemistry , Receptors, Glucagon/agonists , Amino Acid Sequence , Animals , CHO Cells , Cricetinae , Cricetulus , Dogs , Glucagon-Like Peptide-1 Receptor , Humans , Models, Molecular , Molecular Sequence Data , Peptide Library , Peptides/metabolism , Peptides/pharmacology , Structure-Activity RelationshipABSTRACT
We report the identification of potent agonists of the Glucagon-Like Peptide-1 Receptor (GLP-1R). These compounds are short, 11 amino acid peptides containing several unnatural amino acids, including (in particular) analogs of homohomophenylalanine (hhPhe) at the C-terminal position. Typically the functional activity of the more potent peptides in this class is in the low picomolar range in an in vitro cAMP assay, with one example demonstrating excellent in vivo activity in an ob/ob mouse model of diabetes.
Subject(s)
Aminobutyrates/chemistry , Peptides/chemistry , Receptors, Glucagon/agonists , Amino Acid Sequence , Animals , Blood Glucose/drug effects , CHO Cells , Cricetinae , Cricetulus , Glucagon-Like Peptide-1 Receptor , Hyperglycemia/blood , Hyperglycemia/drug therapy , Mice , Molecular Sequence Data , Molecular Structure , Peptides/chemical synthesis , Peptides/pharmacokinetics , Peptides/therapeutic useABSTRACT
Glucagon-like peptide 1 (GLP-1) is a 30 or 31 amino acid peptide hormone that contributes to the physiological regulation of glucose homeostasis and food intake. Herein, we report the discovery of a novel class of 11 amino acid GLP-1 receptor agonists. These peptides consist of a structurally optimized 9-mer, which is closely related to the N-terminal 9 amino acids of GLP-1, linked to a substituted C-terminal biphenylalanine (BIP) dipeptide. SAR studies resulted in 11-mer GLP-1R agonists with similar in vitro potency to the native 30-mer. Peptides 21 and 22 acutely reduced plasma glucose excursions and increased plasma insulin concentrations in a mouse model of diabetes. These peptides also showed sustained exposures over several hours in mouse and dog models. The described 11-mer GLP-1 receptor agonists represent a new tool in further understanding GLP-1 receptor pharmacology that may lead to novel antidiabetic agents.
Subject(s)
Hypoglycemic Agents/chemistry , Hypoglycemic Agents/pharmacology , Oligopeptides/chemistry , Oligopeptides/pharmacology , Receptors, Glucagon/agonists , Amino Acid Sequence , Animals , CHO Cells , Cricetinae , Cricetulus , Dogs , Dose-Response Relationship, Drug , Glucagon-Like Peptide-1 Receptor , Humans , Hypoglycemic Agents/chemical synthesis , Hypoglycemic Agents/pharmacokinetics , Male , Mice , Models, Molecular , Molecular Sequence Data , Oligopeptides/chemical synthesis , Oligopeptides/pharmacokinetics , Protein ConformationABSTRACT
Beta-APP cleaving enzyme (BACE) is responsible for the first of two proteolytic cleavages of the APP protein that together lead to the generation of the Alzheimer's disease-associated Abeta peptide. It is widely believed that halting the production of Abeta peptide, by inhibition of BACE, is an attractive therapeutic modality for the treatment of Alzheimer's disease. BACE is an aspartyl protease, and there is significant effort in the pharmaceutical community to apply traditional design methods to the development of active site-directed inhibitors of this enzyme. We report here the discovery of a ligand binding pocket within the catalytic domain of BACE that is distinct from the enzymatic active site (i.e., an exosite). Peptides, initially identified from combinatorial phage peptide libraries, contain the sequence YPYF(I/L)P(L/I) and bind specifically to this exosite, even in the presence of saturating concentrations of active site-directed inhibitors. Binding of peptides to the BACE exosite leads to a concentration-dependent inhibition of proteolysis for APP-related, protein-based substrates of BACE. The discovery of this exosite opens new opportunities for the identification and development of novel and potentially selective small molecule inhibitors of BACE that act through exosite, rather than active site, binding interactions.
